Manami Moti Department of Pediatric Dentistry,Tsurumi University School of Dental Medicine Roll of occlusion in masseter muscle acetylcholine Ku-0059436 solubility dmso receptor clustering” 4. Yoshie Yamasaki Okayama University Graduate School of Medicine,Dentistry and Pharmaceutical Siences Distribution and molecular characterization of Porphyromonas gulae carrying a new fimA genotype”. 1. Ryota Nomura Department of Pediatric Dentistry, Osaka University Graduate of School Dentistry Identification and characterization of
a collagen-binding protein, Cbm, in Streptococcus mutans 1. Ayuchi Urara Department of Pediatric Dentistry, Osaka University Graduate of School Dentistry Infection of specific strains of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis” 2. Kaido Kumazawa Department of Pediatric Dentistry, Tokyo Dental College Effect of single-dose amoxicillin on rat incisor odontogenesis: a morphological study “
“There are no efficacy trials of the licensed rotavirus vaccines available in India. The data from other developing countries
shows efficacy ranging from 17.6% (in Mali) to 61.2% (in South Africa and Malawi).1, 2, 3, 4 and 5 There is definite gradient in the BIBF 1120 datasheet efficacies of these vaccines when different regions of the world are compared – highest in US and Europe, moderate in Latin America, and low in Africa and Asia.1, 2, 3, 4, 5, 6, 7 and 8 IAPCOI still believes that in developing countries with high rotavirus disease incidence, even moderate to low vaccine efficacy translates into significant numbers of
severe rotavirus gastroenteritis cases prevented and into significant public health impact. More rotavirus disease burden may be prevented in developing countries despite lower vaccine efficacy than in countries with low rotavirus disease burden and higher vaccine efficacy.9 However, considering that oral vaccines elicit diminished immune responses or have lower efficacy in developing countries than in developed countries,10 and since India is having history of poor performance of other oral vaccines, notably OPV in recent past,11, 12 and 13 it would not be prudent Masitinib (AB1010) to extrapolate data from other countries having comparable epidemiologic, economic, and demographic indices. In a recent community-based study from Vellore, it was noted that rotavirus infection generally occurred early in life, levels of re-infection were high and even three natural infections were able to provide only 79% protection against moderate or severe disease, with no evidence of homotypic protection as believed so far.14 Therefore, there may be a need for modification of the rotavirus vaccination strategy in India, by increasing the dose or increasing the number of doses or delaying the doses or even considering neonatal immunization.